Work

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.4513

Authors: Dean F. Bajorin, Padmanee Sharma, David I. Quinn, Elizabeth R. Plimack, Jean H. Hoffman-Censits, Peter H. O'Donnell, Arlene O. Siefker-Radtke, Nadeem Anwar Sheikh, Jennifer Susan LIll, James B. Trager, Leonard G. Gomella

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Fox Chase Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Dendreon (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890268676

Cites:

Cited by: 19

Related to: 10